CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs

Launched by UNIVERSITY OF FLORIDA · Aug 19, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how using a genetic test called CYP2D6 can help doctors prescribe the right amount of pain medication for patients undergoing elective surgery to repair a ventral hernia. The goal is to see if this personalized approach leads to better pain management and improves the quality of life for patients after surgery, compared to standard care practices.

To participate in the trial, you need to be over 18 years old and scheduled for a ventral hernia repair that is at least 1.5 cm in size and will use mesh. Unfortunately, if your hernia is smaller than that, if you've had a primary repair without mesh, or if you're on long-term opioid medications, you won't be eligible. Participants will be closely monitored to see how well this approach works and what effects it has on pain and recovery. If you're selected, you can expect to be part of a study that aims to improve pain management for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • \> 18 years age undergoing a ventral hernia repair (VHR) ≥1.5 cm in diameter with mesh.
• Exclusion Criteria:
• • ventral hernia \<1.5 cm
• • primary ventral hernia repair (VHR) without a mesh
• • emergency operative procedure
• • receiving chronic opioid therapy (defined as use of opioids on most days for \>3 months)
• • allergy to opioids
• • women of childbearing potential who have a positive pregnancy result as part of their standard pre-surgical workup